A Phase 1/2 interventional study of Probiotic Therapy With Gegen Qinlian Tang in Acute Radiation Enteritis, sponsored by Jiujiang No.1 People's Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Jiujiang No.1 People's Hospital · Phase 1/2, Interventional, and Prevention
The purpose of this clinical study is to evaluate whether Bifidobacterium Triple Viable Capsules, alone or in combination with Gegen Qinlian Decoction, can effectively prevent and treat acute radiation enteritis in patients undergoing abdominal or pelvic radiotherapy.
The study aims to answer the following question: Can probiotics, with or without the addition of herbal medicine, reduce the incidence and severity of radiation-induced intestinal injury and improve the quality of life for patients during and after radiotherapy?
A total of 60 patients with malignant tumors receiving abdominal or pelvic radiotherapy will be recruited and randomly assigned to one of three groups: a control group (no intervention), a probiotics-only group (Bifidobacterium Triple Viable Capsules, three capsules twice daily), and a combination therapy group (probiotics with modified Gegen Qinlian Decoction tailored to individual symptoms).
The primary outcome will be the incidence and severity of acute radiation enteritis, assessed using the RTOG/EORTC grading criteria (0-IV levels). Daily observations will be recorded during radiotherapy, with follow-up lasting three months after the completion of treatment.
This study seeks to provide evidence for the use of probiotics and herbal medicine as effective strategies to mitigate the side effects of radiotherapy and improve patient outcomes.
34 studies on the registry are indexed under Enteritis; 7 are open to participants now.
This study's planned enrollment of 60 is above the median of 53 across 26 interventional studies indexed under Enteritis.
Browse Enteritis studies →Jiujiang No.1 People's Hospital is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:1.Age:Participants aged 18 to 80 years.2.Diagnosis:
Patients diagnosed with malignant tumors confirmed by cytological or pathological examination.Patients scheduled for abdominal or pelvic radiotherapy based on treatment guidelines.3Cognitive and Communication Ability:Participants must have clear consciousness and normal cognitive abilities to communicate effectively.4.Consent:Participants must provide written and agree to participate in the study.
Family members must also provide consent if applicable.5.Willingness to Cooperate:Participants must be willing to comply with the study procedures and requirements.
Exclusion Criteria:1.History of Severe Intestinal Diseases:Patients with a history of severe intestinal diseases, including ischemic bowel disease, ulcerative colitis, Crohn's disease, or other chronic inflammatory bowel conditions.2.Recent Antibiotic Use:Patients who have received antibiotic treatment within the past 2 years.3.Severe Organ Dysfunction:Patients with severe liver or kidney dysfunction, as determined by clinical assessment or laboratory tests.4.Comorbidities and Other Major Diseases:
Patients with other serious illnesses that may interfere with the study protocol or compliance, including but not limited to cardiovascular, respiratory, or neurological diseases.5.Inability to Participate:Patients unable to cooperate with the study procedures due to physical or psychological reasons.Patients who are likely to withdraw midway through the study.6.Incomplete Medical Records or Refusal to Share Data:Patients who refuse to share their medical records or have incomplete medical documentation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive an oral placebo matched in appearance to the Bifidobacterium Triple Viable Capsules, taken three times daily for 8 weeks. No active interventions will be administered in this group, serving as the placebo control.
Drug: Probiotic Therapy With Gegen Qinlian Tang
This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily) for 8 weeks. The combination therapy is designed specifically for the prevention and treatment of radiation enteritis, differentiating it from probiotics or herbal therapies used alone.
Incidence of Acute Radiation Enteritis
The incidence of acute radiation enteritis will be assessed using the RTOG/EORTC grading criteria (Grade 0-IV). Symptoms such as diarrhea, abdominal pain, and mucus secretion will be monitored daily during radiotherapy and up to three months post-treatment. The outcome will measure the proportion of patients experiencing Grade II or higher symptoms in each study arm. This assessment aims to evaluate the effectiveness of Bifidobacterium Triple Viable Capsules, alone or in combination with Gegen Qinlian Decoction, in reducing the incidence of radiation enteritis.
Time frame: From the start of radiotherapy to 3 months post-treatment
Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiujiang No.1 People's Hospital